Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci Corporation (Nasdaq: ABSI) reported its financial results for Q2 2021, showing a revenue of $0.7 million, up from $0.6 million in Q2 2020. The company recorded a significant net loss of $41.2 million, driven by increased R&D expenses of $11.0 million and SG&A expenses of $5.2 million. Key highlights include the acquisition of Totient, the completion of an IPO raising approximately $210 million, and the expansion of its workforce by over 100 employees. Absci also signed key agreements with PhaseBio and Alpha Cancer Technologies to advance its Integrated Drug Creation™ Platform.
Absci Corporation announced the closing of its initial public offering (IPO) on July 26, 2021, raising $230 million by selling 14,375,000 shares of common stock at $16.00 per share. The offering included full exercise of the underwriters' option for an additional 1,875,000 shares. Absci's stock began trading on the Nasdaq Global Select Market under the ticker symbol ABSI on July 22, 2021. Leading underwriters included J.P. Morgan, Credit Suisse, and BofA Securities.
Absci Corporation has announced the pricing of its initial public offering (IPO) of 12,500,000 shares at a price of $16.00 per share. The offering is expected to generate gross proceeds of $200.0 million, not including underwriters' options. Trading on the Nasdaq under the ticker symbol ABSI begins on July 22, 2021, with the offering closing anticipated on July 26, 2021, pending customary conditions. Notable managers for this IPO include J.P. Morgan, Credit Suisse, and others.
Absci Corporation has filed a registration statement on Form S-1 with the SEC for a proposed initial public offering (IPO) of its common stock. The number of shares and price range are yet to be determined. Absci aims to list its stock on The Nasdaq Global Market under the symbol ABSI. Joint book running managers for the offering include J.P. Morgan, Credit Suisse, BofA Securities, Cowen, and Stifel. This filing does not constitute an offer to sell securities prior to registration.